A protein that may help glioma cells survive radiation
Original title: USP4-Mediated Deubiquitination of PTBP1 Promotes Glioma Progression and Radioresistance by Enhancing PHB2-Dependent Mitophagy.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done in animals, not people. Most findings at this stage never become treatments.
This was only done in lab cells and in mice.
The short version
In lab tests, a protein called PTBP1 helped brain tumor cells live through radiation.
What was studied. Researchers studied glioma: A tumor that starts in the glial cells. Those are the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4. The grade says how the tumor is expected to act. See the glossary cells and glioma tissue in the lab. They also grew glioma tumors in mice. They turned certain proteins up or down, then gave radiation.
What they found. glioma: A tumor that starts in the glial cells. Those are the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4. The grade says how the tumor is expected to act. See the glossary tissue and cells had high levels of a protein called PTBP1. Raising PTBP1 made cells grow more, die less, and handle radiation better. Another protein, USP4, kept PTBP1 from being broken down. Lowering PTBP1 took these effects away in cells and in mice.
What this means, and what it doesn't
What it could mean: This points to a possible target for future drugs. Blocking these proteins might one day make radiation work better. Nothing here is a treatment a patient can ask for.
What it doesn't mean: This does not mean a new treatment is ready. The work was done in cells in a dish and in mice, not in people. No person was treated in this study. It is very early science, and it is not a cure. The authors say more testing is still needed.
Source: PubMed, October 25, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.